[â—€è¿”å›](./home.md)

# ä¾æ›¿å”‘ä»‘ (Etizolam)

> ã€Šä¸»æ’­å¥³å­©é‡åº¦ä¾èµ–ã€‹ä¸­ç³–ç³–odçš„è¯ç‰©ä¹‹ä¸€ï¼Œæ²¡æƒ³åˆ°å®ƒä½œä¸ºç­–åˆ’è¯å±…ç„¶ä¸€åº¦æµè¡Œ

<mark>è´¨é‡ç›¸å½“é«˜äº†ï¼Œç›®å‰çœ‹ä¸‹æ¥æ²¡æœ‰è¯¯ç”¨çš„é“¾æ¥ï¼Œå¥½è¯„ï¼-20260125</mark>

![Skull and crossbones darktextred2.png](../æ–‡ä»¶/Skull_and_crossbones_darktextred2.png)

**å½“[å™»å©äºŒæ°®å“ç±»ç‰©è´¨](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å™»å©äºŒæ°®å“ç±»ç‰©è´¨.md)ä¸[é˜¿ç‰‡ç±»](../æ–‡æ¡£/è¯ç‰©åº”å¯¹æªæ–½/anti-é˜¿ç‰‡ç±».md)ã€[è‹¯äºŒæ°®å“ç±»è¯ç‰©](../æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦/è‹¯äºŒæ°®å“ç±»è¯ç‰©.md)ã€[å·´æ¯”å¦¥ç±»](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å·´æ¯”å¦¥ç±».md)ã€[åŠ å·´å–·ä¸ç±»](../æ–‡æ¡£/è¯ç‰©åº”å¯¹æªæ–½/anti-åŠ å·´å–·ä¸ç±».md)ã€[é…’ç²¾](../è¯ç‰©/é…’ç²¾.md)æˆ–å…¶ä»–[GABAèƒ½ç‰©è´¨](../æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦/GABA.md)ç­‰å…¶ä»–[æŠ‘åˆ¶å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md)è”ç”¨æ—¶ï¼Œå¯èƒ½ä¼šå¯¼è‡´è‡´å‘½çš„[è¿‡é‡](../æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦/è¯ç‰©è¿‡é‡çš„æ•‘åŠ©æ–¹æ³•.md)ã€‚**

å¼ºçƒˆå»ºè®®ä¸è¦æ··ç”¨è¿™äº›ç‰©è´¨ï¼Œå°¤å…¶æ˜¯åœ¨[ä¸­ç­‰](../è¯æ•ˆ/home.md)åˆ°[ä¸¥é‡](../è¯æ•ˆ/home.md)å‰‚é‡ä¸‹ã€‚

---

| **ä¾æ›¿å”‘ä»‘ (Etizolam)** | |
| --- | --- |
| [![Etizolam.svg](../æ–‡ä»¶/Etizolam.svg)](../æ–‡ä»¶/Etizolam.svg) | |
| **åŒ–å­¦å‘½å** | |
| ä¿—å | *Etizolam, Etilaam, Etizest, Depas* |
| å–ä»£åç§° | *Etizolam* |
| ç³»ç»Ÿå‘½å | *4-(2-Chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine* |
| **åˆ†ç±»** | |
| ç²¾ç¥è¯ç‰©ç±»å‹ | *[æŠ‘åˆ¶å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md)* |
| åŒ–å­¦ç±»å‹ | *[å™»å©äºŒæ°®å“ç±»ç‰©è´¨](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å™»å©äºŒæ°®å“ç±»ç‰©è´¨.md) / å™»å©ä¸‰å”‘äºŒæ°®å“* |
| **ç»™è¯é€”å¾„** | |
| **è­¦å‘Šï¼š** ç”±äºä¸ªä½“ä½“é‡ã€è€å—æ€§ã€ä»£è°¢å’Œä¸ªäººæ•æ„Ÿåº¦çš„å·®å¼‚ï¼Œè¯·åŠ¡å¿…ä»ä½å‰‚é‡å¼€å§‹ã€‚[å¦è§ä¼¤å®³å‡å°‘æªæ–½ç« èŠ‚](../æ–‡æ¡£/å…³äºæœ¬ç«™/home.md)ã€‚ | **â‡£ [å£æœ](../æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦/ç»™è¯é€”å¾„.md)** |
| **[å‰‚é‡](../æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦/å‰‚é‡.md)** | |
| [ç”Ÿç‰©åˆ©ç”¨åº¦](../æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦/ç”Ÿç‰©åˆ©ç”¨åº¦.md) | 93% |
| [é˜ˆå€¼](../è¯æ•ˆ/home.md) | 0.2 mg |
| [è½»å¾®](../è¯æ•ˆ/home.md) | 0.5 - 1 mg |
| [ä¸­ç­‰](../è¯æ•ˆ/home.md) | 1 - 2 mg |
| [å¼ºçƒˆ](../è¯æ•ˆ/home.md) | 2 - 5 mg |
| [ä¸¥é‡](../è¯æ•ˆ/home.md) | 5 mg + |
| **[æ—¶é•¿](../æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦/æ—¶é•¿.md)** | |
| [æ€»æ—¶é•¿](../è¯æ•ˆ/home.md) | 5 - 7 å°æ—¶ |
| [è¯æ•ˆå‘ä½œ](../è¯æ•ˆ/home.md) | 15 - 30 åˆ†é’Ÿ |
| [è¯æ•ˆä¸Šå‡](../è¯æ•ˆ/home.md) | 30 - 60 åˆ†é’Ÿ |
| [è¯æ•ˆè¾¾å³°](../è¯æ•ˆ/home.md) | 2 - 3 å°æ—¶ |
| [è¯æ•ˆè¤ªå»](../è¯æ•ˆ/home.md) | 1.5 - 2.5 å°æ—¶ |
| [è¯æ•ˆæ®‹ä½™](../è¯æ•ˆ/home.md) | 6 - 24 å°æ—¶ |
| **[å…è´£å£°æ˜](../æ–‡æ¡£/å…³äºæœ¬ç«™/home.md)ï¼š** æœ¬ç«™çš„[å‰‚é‡](../æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦/å‰‚é‡.md)ä¿¡æ¯æ”¶é›†è‡ªç”¨æˆ·å’Œ[ç½‘ç»œèµ„æº](../æ–‡æ¡£/å…³äºæœ¬ç«™/home.md)ï¼Œä»…ä¾›æ•™è‚²ç›®çš„ã€‚å®ƒä¸æ˜¯æ¨èï¼Œåº”ä¸å…¶ä»–æ¥æºæ ¸å®ä»¥ç¡®ä¿å‡†ç¡®æ€§ã€‚ | |
| **[è¯ç‰©è”ç”¨](#dangerous_interactions)** | |

**ä¾æ›¿å”‘ä»‘**ï¼ˆEtizolamï¼Œä¹Ÿè¢«ç§°ä¸º **Etilaam**ã€**Etizest**ã€**Depas** ç­‰ï¼‰æ˜¯[å™»å©äºŒæ°®å“ç±»](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å™»å©äºŒæ°®å“ç±»ç‰©è´¨.md)çš„ä¸€ç§æ–°å‹[æŠ‘åˆ¶å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md)ã€‚ä¾æ›¿å”‘ä»‘åœ¨åŒ–å­¦ç»“æ„ä¸Šä¸[è‹¯äºŒæ°®å“ç±»è¯ç‰©](../æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦/è‹¯äºŒæ°®å“ç±»è¯ç‰©.md)ç›¸å…³ï¼Œé€šè¿‡ç»“åˆå¤§è„‘ä¸­çš„ [GABA](../æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦/GABA.md) å—ä½“å‘æŒ¥ä½œç”¨ã€‚

ä¾æ›¿å”‘ä»‘ä¸æ˜¯å¸¸ç”¨çš„å¤„æ–¹è¯ã€‚å®ƒä½œä¸º[ç ”ç©¶åŒ–å­¦å“](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/ç ”ç©¶åŒ–å­¦å“.md)åœ¨ç½‘ä¸Šå‡ºå”®ï¼Œé€šå¸¸è¢«ç”¨ä½œ[é˜¿æ™®å”‘ä»‘](./é˜¿æ™®å”‘ä»‘.md)ï¼ˆ**Xanax**ï¼‰æˆ–[åœ°è¥¿æ³®](./åœ°è¥¿æ³®.md)ï¼ˆ**Valium**ï¼‰ç­‰è¯ç”¨è‹¯äºŒæ°®å“ç±»è¯ç‰©çš„æ›¿ä»£å“ã€‚ä¾æ›¿å”‘ä»‘å¸¸è§å½¢å¼ä¸ºé¢—ç²’æˆ–è¯ç‰‡ã€å¸å¢¨çº¸ã€ä¸™äºŒé†‡æº¶æ¶²æˆ–çº¯ç²‰æœ«ã€‚

[ä¸»è§‚æ•ˆåº”](../è¯æ•ˆ/home.md)åŒ…æ‹¬[ç„¦è™‘æŠ‘åˆ¶](../è¯æ•ˆ/home.md)ã€[å»æŠ‘åˆ¶](../è¯æ•ˆ/home.md)ã€[è‚Œè‚‰æ¾å¼›](../è¯æ•ˆ/è‚Œè‚‰æ¾å¼›.md)ã€[é•‡é™](../è¯æ•ˆ/é•‡é™.md)å’Œ[æ¬£å¿«æ„Ÿ](../è¯æ•ˆ/èº¯ä½“æ¬£å¿«æ„Ÿ.md)ã€‚ç”±äºè¿™äº›é€”å¾„çš„é«˜ç”Ÿç‰©åˆ©ç”¨åº¦ï¼Œä¾æ›¿å”‘ä»‘é€šå¸¸é€šè¿‡[å£æœ](../æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦/ç»™è¯é€”å¾„.md)å’Œ[èˆŒä¸‹å«æœ](../æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦/ç»™è¯é€”å¾„.md)ç»™è¯ã€‚

ä¸[è‹¯äºŒæ°®å“ç±»è¯ç‰©](../æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦/è‹¯äºŒæ°®å“ç±»è¯ç‰©.md)ä¸€æ ·ï¼Œå¯¹äºé•¿æœŸæˆ–é‡åº¦ä½¿ç”¨è€…æ¥è¯´ï¼Œ[çªç„¶åœç”¨å™»å©äºŒæ°®å“ç±»ç‰©è´¨](../æ–‡æ¡£/è¯ç‰©åº”å¯¹æªæ–½/è¯ç‰©æˆ’é™¤/æˆ’æ–­ååº”.md)å¯èƒ½æ˜¯å±é™©çš„ï¼Œç”šè‡³å±åŠç”Ÿå‘½ã€‚å› æ­¤ï¼Œå¼ºçƒˆå»ºè®®å¯¹è¯¥ç‰©è´¨äº§ç”Ÿç”Ÿç†ä¾èµ–çš„ä¸ªä½“é€šè¿‡åœ¨è¾ƒé•¿æ—¶é—´å†…é€æ¸å‡å°‘æ¯æ—¥æ‘„å…¥é‡æ¥[é€’å‡](../æ–‡æ¡£/è¯ç‰©åº”å¯¹æªæ–½/è¯ç‰©æˆ’é™¤/home.md)å‰‚é‡ï¼Œè€Œä¸æ˜¯çªç„¶åœæ­¢ä½¿ç”¨ã€‚

ç”±äºå…¶æé«˜çš„æ»¥ç”¨å’Œæˆç˜¾æ½œåŠ›ï¼Œå¦‚æœä½¿ç”¨è¯¥ç‰©è´¨ï¼Œå¼ºçƒˆå»ºè®®é‡‡å–é€‚å½“çš„[ä¼¤å®³å‡å°‘æªæ–½](../æ–‡æ¡£/å…³äºæœ¬ç«™/home.md)ã€‚

## ç›®å½•

1.  [å†å²ä¸æ–‡åŒ–](#history_and_culture)
2.  [åŒ–å­¦](#chemistry)
3.  [è¯ç†å­¦](#pharmacology)
4.  [ä¸»è§‚æ•ˆåº”](#subjective_effects)
    *   4.1 [èº¯ä½“æ•ˆåº”](#physical_effects)
    *   4.2 [åå¸¸æ•ˆåº”](#paradoxical_effects)
    *   4.3 [è®¤çŸ¥æ•ˆåº”](#cognitive_effects)
    *   4.4 [è¯æ•ˆæ®‹ä½™](#after_effects)
    *   4.5 [ä½“éªŒæŠ¥å‘Š](#experience_reports)
5.  [æ¯’æ€§ä¸ä¼¤å®³æ½œåŠ›](#toxicity_and_harm_potential)
    *   5.1 [è€å—æ€§ä¸æˆç˜¾æ½œåŠ›](#tolerance_and_addiction_potential)
    *   5.2 [è¿‡é‡](#overdose)
    *   5.3 [å±é™©çš„è¯ç‰©è”ç”¨](#dangerous_interactions)
6.  [æ³•å¾‹åœ°ä½](#legal_status)
7.  [å¦è§](#see_also)
8.  [å¤–éƒ¨é“¾æ¥](#external_links)
9.  [æ–‡çŒ®](#literature)
10. [å‚è€ƒèµ„æ–™](#references)

## å†å²ä¸æ–‡åŒ–

| ![History icon.svg](../æ–‡ä»¶/History_icon.svg) | **æ­¤ *å†å²ä¸æ–‡åŒ–* ç« èŠ‚æ˜¯ä¸€ä¸ª[å°ä½œå“](../æ–‡æ¡£/å…³äºæœ¬ç«™/home.md)ã€‚**<br>å› æ­¤ï¼Œå®ƒå¯èƒ½åŒ…å«ä¸å®Œæ•´æˆ–é”™è¯¯çš„ä¿¡æ¯ã€‚ |
| --- | --- |

ä¾æ›¿å”‘ä»‘äº 2011 å¹´é¦–æ¬¡å‡ºç°åœ¨åœ¨çº¿[ç ”ç©¶åŒ–å­¦å“](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/ç ”ç©¶åŒ–å­¦å“.md)å¸‚åœºä¸Šã€‚ä»é‚£æ—¶èµ·ï¼Œå®ƒçš„å—æ¬¢è¿ç¨‹åº¦ç¨³æ­¥ä¸Šå‡ã€‚è¿™å¯èƒ½å½’å› äºå®ƒçš„ä½æˆæœ¬å’Œå……è¶³çš„ä¾›åº”ï¼Œä»¥åŠå®ƒä¸å¨±ä¹æ€§è‹¯äºŒæ°®å“ç±»è¯ç‰©ä¸€æ ·å…·æœ‰é«˜åº¦çš„ä¾èµ–æ€§å’Œæˆç˜¾æ€§ã€‚

ä¾æ›¿å”‘ä»‘ä¸å¤§å¤šæ•°å…¶ä»–ç ”ç©¶åŒ–å­¦å“ä¸åŒï¼Œå®ƒåœ¨ä¸–ç•Œè®¸å¤šå›½å®¶è¢«æ‰¹å‡†å¹¶ä½œä¸ºæ²»ç–—ç„¦è™‘ç—‡çš„è¯ç‰©ç§¯æå¤„æ–¹ï¼Œå¸¸è§çš„å“ç‰Œåç§°å¦‚ *Etilaam* å’Œ *Etizest*ã€‚å…¶ä½œä¸ºè¯ç‰©çš„èµ·æºå°šä¸æ¸…æ¥šï¼Œå°½ç®¡æ—©åœ¨ 1990 å¹´ä»£å°±æœ‰åŒ»å­¦è®ºæ–‡å¼•ç”¨å…¶ç”¨äºæ²»ç–—ç„¦è™‘ç—‡ã€‚

## åŒ–å­¦

ä¾æ›¿å”‘ä»‘æ˜¯[è‹¯äºŒæ°®å“ç±»è¯ç‰©](../æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦/è‹¯äºŒæ°®å“ç±»è¯ç‰©.md)çš„ç»“æ„è¿‘äº²ï¼Œå…¶ä¸­è‹¯ç¯è¢«å™»å©ç¯å–ä»£ï¼Œå°†å…¶å½’ç±»ä¸º[å™»å©äºŒæ°®å“ç±»ç‰©è´¨](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å™»å©äºŒæ°®å“ç±»ç‰©è´¨.md)ã€‚å™»å©æ˜¯ä¸€ä¸ªå«æœ‰ä¸€ä¸ªç¡«åŸå­çš„äº”å…ƒèŠ³é¦™ç¯ã€‚ä¾æ›¿å”‘ä»‘åŒ…å«ä¸€ä¸ªå™»å©ç¯ï¼Œè¯¥ç¯ä¸äºŒæ°®å“ç¯ç¨ åˆï¼ŒäºŒæ°®å“ç¯æ˜¯ä¸€ä¸ªä¸ƒå…ƒç¯ï¼Œåœ¨ R1 å’Œ R4 ä½ç½®æœ‰ä¸¤ä¸ªæ°®æˆåˆ†ã€‚è¿™æ„æˆäº†ä¾æ›¿å”‘ä»‘çš„å™»å©äºŒæ°®å“æ ¸å¿ƒã€‚ä¸€æ¡ä¹™åŸºé“¾ç»“åˆåœ¨ R7 ä½ç½®çš„è¿™ç§åŒç¯ç»“æ„ä¸Šã€‚æ­¤å¤–ï¼Œä¸€ä¸ª R2' æ°¯å–ä»£çš„è‹¯ç¯ç»“åˆåœ¨ R5 ä½ç½®çš„è¿™ç§ç»“æ„ä¸Šã€‚

ä¾æ›¿å”‘ä»‘è¿˜å«æœ‰ä¸€ä¸ªç”²åŸºåŒ–çš„ä¸‰å”‘ç¯ï¼Œè¯¥ç¯ä¸äºŒæ°®å“ç¯çš„ R1 å’Œ R2 ç¨ åˆå¹¶ç»“åˆã€‚ä¾æ›¿å”‘ä»‘ä¸æŸäº›[è‹¯äºŒæ°®å“ç±»](../æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦/è‹¯äºŒæ°®å“ç±»è¯ç‰©.md)è¯ç‰©ï¼ˆç§°ä¸ºä¸‰å”‘è‹¯äºŒæ°®å“ç±»ï¼Œä»¥åç¼€â€œ-zolamâ€åŒºåˆ†ï¼‰å…±äº«è¿™ç§ç¨ åˆçš„ä¸‰å”‘ç¯å–ä»£åŸºã€‚

## è¯ç†å­¦

å™»å©äºŒæ°®å“ç±»ç‰©è´¨é€šè¿‡ä¸ GABA-A å—ä½“å¤åˆç‰©ä¸Šçš„è‹¯äºŒæ°®å“ç»“åˆä½ç‚¹ï¼ˆä»¥å‰ç§°ä¸º BZD å—ä½“ï¼‰ç»“åˆäº§ç”Ÿå„ç§æ•ˆåº”ï¼Œé€šè¿‡å¢åŠ ç¥ç»é€’è´¨[Î³-æ°¨åŸºä¸é…¸ (GABA)](../æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦/GABA.md) ä¸å…¶è‡ªèº«[å—ä½“](../æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦/å—ä½“è›‹ç™½.md)ç»“åˆçš„èƒ½åŠ›ï¼Œæ”¾å¤§å…¶åŠŸæ•ˆå’Œä½œç”¨ã€‚è¿™è¢«ç§°ä¸ºæ­£å‘å˜æ„è°ƒèŠ‚ã€‚ç”±äºè¯¥ä½ç‚¹æ˜¯å¤§è„‘ä¸­æœ€å¤šäº§çš„æŠ‘åˆ¶æ€§å—ä½“ç»„ï¼Œå…¶è°ƒèŠ‚å¯¼è‡´ä¾æ›¿å”‘ä»‘å¯¹ç¥ç»ç³»ç»Ÿçš„[é•‡é™](../è¯æ•ˆ/é•‡é™.md)ï¼ˆæˆ–[é•‡é™ä½œç”¨](../è¯æ•ˆ/é•‡é™.md)ï¼‰ã€‚

## ä¸»è§‚æ•ˆåº”

è½¶äº‹æŠ¥å‘Šè¡¨æ˜ï¼Œå°±å…¶ç›¸å¯¹æ•ˆåŠ›è€Œè¨€ï¼Œ1 æ¯«å…‹ä¾æ›¿å”‘ä»‘å¤§çº¦ç›¸å½“äº 0.5 æ¯«å…‹[é˜¿æ™®å”‘ä»‘](./é˜¿æ™®å”‘ä»‘.md)ï¼ˆ**Xanax**ï¼‰ã€0.5 æ¯«å…‹[æ°¯ç¡è¥¿æ³®](./æ°¯ç¡è¥¿æ³®.md)ï¼ˆ**Klonopin**ï¼‰æˆ– 10 æ¯«å…‹[åœ°è¥¿æ³®](./åœ°è¥¿æ³®.md)ï¼ˆ**Valium**ï¼‰ã€‚åœ¨èµ·æ•ˆé€Ÿåº¦ã€æ€»æŒç»­æ—¶é—´å’Œå¨±ä¹æ•ˆæœæ–¹é¢ï¼Œå®ƒé€šå¸¸è¢«æ¯”ä½œæ•ˆåŠ›è¾ƒä½ä¸”å…·æœ‰[é•‡é™](../è¯æ•ˆ/é•‡é™.md)ä½œç”¨çš„[é˜¿æ™®å”‘ä»‘](./é˜¿æ™®å”‘ä»‘.md)ã€‚

***å…è´£å£°æ˜ï¼š** ä¸‹åˆ—æ•ˆåº”å¼•ç”¨è‡ª[***ä¸»è§‚æ•ˆåº”ç´¢å¼•***](../æ–‡æ¡£/å…³äºæœ¬ç«™/home.md) (**SEI**)ï¼Œè¿™æ˜¯ä¸€ä¸ªåŸºäºè½¶äº‹ç”¨æˆ·æŠ¥å‘Šå’Œ [PsychonautWiki](../æ–‡æ¡£/å…³äºæœ¬ç«™/home.md) è´¡çŒ®è€…ä¸ªäººåˆ†æçš„å¼€æ”¾ç ”ç©¶æ–‡çŒ®ã€‚å› æ­¤ï¼Œåº”ä»¥å¥åº·çš„æ€€ç–‘æ€åº¦çœ‹å¾…å®ƒä»¬ã€‚*

*åŒæ ·å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œè¿™äº›æ•ˆåº”ä¸ä¸€å®šä¼šä»¥å¯é¢„æµ‹æˆ–å¯é çš„æ–¹å¼å‘ç”Ÿï¼Œå°½ç®¡è¾ƒé«˜çš„å‰‚é‡æ›´å¯èƒ½è¯±å‘å…¨æ–¹ä½çš„æ•ˆåº”ã€‚åŒæ ·ï¼Œ**ä¸è‰¯ååº”**éšç€å‰‚é‡çš„å¢åŠ è€Œå˜å¾—è¶Šæ¥è¶Šå¯èƒ½ï¼Œå¹¶å¯èƒ½åŒ…æ‹¬**æˆç˜¾ã€ä¸¥é‡ä¼¤å®³æˆ–æ­»äº¡*** â˜ ã€‚

### **èº¯ä½“æ•ˆåº”**

*   **[é•‡é™](../è¯æ•ˆ/é•‡é™.md)** - ä¾æ›¿å”‘ä»‘å…·æœ‰å¿«é€Ÿèµ·æ•ˆçš„é•‡é™ä½œç”¨ã€‚åœ¨é«˜å‰‚é‡ä¸‹ï¼Œè¿™å¯èƒ½å¯¼è‡´ä½¿ç”¨è€…çªç„¶æ„Ÿè§‰æåº¦ç¡çœ ä¸è¶³ï¼Œå¥½åƒå‡ å¤©æ²¡ç¡ä¸€æ ·ï¼Œè¿«ä½¿ä»–ä»¬åä¸‹ï¼Œé€šå¸¸æ„Ÿè§‰å¥½åƒéšæ—¶ä¼šæ˜å€’ï¼Œè€Œä¸æ˜¯ä»äº‹ä½“åŠ›æ´»åŠ¨ã€‚è¿™ç§ç¡çœ ä¸è¶³çš„æ„Ÿè§‰ä¸å‰‚é‡æˆæ­£æ¯”ï¼Œæœ€ç»ˆå˜å¾—å¼ºå¤§åˆ°è¶³ä»¥è¿«ä½¿äººå®Œå…¨å¤±å»çŸ¥è§‰ã€‚
*   **[è‚Œè‚‰æ¾å¼›](../è¯æ•ˆ/è‚Œè‚‰æ¾å¼›.md)** - è¿™ç§æ•ˆåº”å¯ä»¥æè¿°ä¸ºç±»ä¼¼äº[åœ°è¥¿æ³®](./åœ°è¥¿æ³®.md)ï¼Œå°½ç®¡æ ¹æ®å‰‚é‡çš„ä¸åŒï¼Œæ˜¾è‘—ç¨‹åº¦ä¸ºè½»åº¦åˆ°ä¸­åº¦ã€‚0.5-1mg å·¦å³çš„ä½å‰‚é‡é€šå¸¸ä¼šå¼•èµ·ä¸[é˜¿æ™®å”‘ä»‘](./é˜¿æ™®å”‘ä»‘.md)ç›¸å½“çš„æ•ˆæœã€‚
*   **[èº¯ä½“æ¬£å¿«æ„Ÿ](../è¯æ•ˆ/èº¯ä½“æ¬£å¿«æ„Ÿ.md)**
*   **[è¿åŠ¨æ§åˆ¶ä¸§å¤±](../è¯æ•ˆ/è¿åŠ¨æ§åˆ¶ä¸§å¤±.md)**
*   **[å‘¼å¸æŠ‘åˆ¶](../è¯æ•ˆ/å‘¼å¸æŠ‘åˆ¶.md)**
*   **[æ€§æ¬²å¢å¼º](../è¯æ•ˆ/æ€§æ¬²å¢å¼º.md)**
*   **[ç™«ç—«å‘ä½œæŠ‘åˆ¶](../è¯æ•ˆ/ç™«ç—«å‘ä½œæŠ‘åˆ¶.md)**
*   **[é£Ÿæ¬²å¢å¼º](../è¯æ•ˆ/é£Ÿæ¬²å¢å¼º.md)** - è¿™ç§æ•ˆæœå¹¶ä¸æ˜¯ç‰¹åˆ«æ˜¾è‘—ï¼Œä½†æ®æŠ¥é“åœ¨æŸäº›äººèº«ä¸Šä¼šå‘ç”Ÿã€‚å½“ä¸[å¤§éº»](../è¯ç‰©/å››æ°¢å¤§éº»é…šï¼ˆTHCï¼‰.md)è”ç”¨æ—¶ï¼Œå®ƒä¼šäº§ç”ŸååŒä½œç”¨ã€‚
*   **[å¤´æ™•](../è¯æ•ˆ/å¤´æ™•.md)**
*   **[æš‚æ—¶æ€§å‹ƒèµ·åŠŸèƒ½éšœç¢](../è¯æ•ˆ/æš‚æ—¶æ€§å‹ƒèµ·åŠŸèƒ½éšœç¢.md)**

### **åå¸¸æ•ˆåº”**

*   å¯¹[è‹¯äºŒæ°®å“ç±»è¯ç‰©](../æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦/è‹¯äºŒæ°®å“ç±»è¯ç‰©.md)çš„åå¸¸ååº”ï¼Œå¦‚ç™«ç—«å‘ä½œå¢åŠ ï¼ˆåœ¨ç™«ç—«æ‚£è€…ä¸­ï¼‰ã€æ”»å‡»æ€§ã€ç„¦è™‘å¢åŠ ã€æš´åŠ›è¡Œä¸ºã€å†²åŠ¨æ§åˆ¶ä¸§å¤±ã€æ˜“æ€’å’Œè‡ªæ€è¡Œä¸ºæœ‰æ—¶ä¼šå‘ç”Ÿï¼ˆå°½ç®¡å®ƒä»¬åœ¨æ™®é€šäººç¾¤ä¸­å¾ˆå°‘è§ï¼Œå‘ç”Ÿç‡ä½äº 1%ï¼‰ã€‚è¿™äº›åå¸¸æ•ˆåº”åœ¨å¨±ä¹æ€§æ»¥ç”¨è€…ã€ç²¾ç¥éšœç¢æ‚£è€…ã€å„¿ç«¥å’Œé«˜å‰‚é‡æ²»ç–—æ‚£è€…ä¸­å‘ç”Ÿçš„é¢‘ç‡æ›´é«˜ã€‚è™½ç„¶æ²¡æœ‰æ­£å¼ç ”ç©¶ï¼Œä½†æ¨æµ‹å™»å©äºŒæ°®å“ç±»ç‰©è´¨ä¹Ÿå­˜åœ¨è¿™ç§é£é™©ã€‚

### **è®¤çŸ¥æ•ˆåº”**

*   **[ç„¦è™‘æŠ‘åˆ¶](../è¯æ•ˆ/home.md)**
*   **[å»æŠ‘åˆ¶](../è¯æ•ˆ/home.md)**
*   **[è®¤çŸ¥æ¬£å¿«æ„Ÿ](../è¯æ•ˆ/home.md)** - è¿™ç§æ•ˆæœé€šå¸¸åªåœ¨é«˜å‰‚é‡ä¸‹äº§ç”Ÿï¼Œå¹¶ä¸”è¢«è®¤ä¸ºå¾ˆå¤§ç¨‹åº¦ä¸Šæºäºä½¿ç”¨è€…åŸæœ‰[ç„¦è™‘](../è¯æ•ˆ/home.md)çš„é‡Šæ”¾ã€‚è®¸å¤šä½¿ç”¨è€…æŠ¥å‘Šè¯´ï¼Œä»[è‹¯äºŒæ°®å“ç±»è¯ç‰©](../æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦/è‹¯äºŒæ°®å“ç±»è¯ç‰©.md)æˆ–åƒä¾æ›¿å”‘ä»‘è¿™æ ·çš„[å™»å©äºŒæ°®å“ç±»ç‰©è´¨](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å™»å©äºŒæ°®å“ç±»ç‰©è´¨.md)ä¸­æ ¹æœ¬æ„Ÿè§‰ä¸åˆ°ä»»ä½•æ„‰æ‚¦æˆ–æ¬£å¿«æ„Ÿã€‚
*   **[å¼ºè¿«æ€§åŠ é‡](../è¯æ•ˆ/home.md)** - å¼ºè¿«æ€§åŠ é‡å¾ˆå¯èƒ½æ˜¯ç”±äºè¯¥ç‰©è´¨äº§ç”Ÿç¼“è§£ç„¦è™‘ã€æ”¾æ¾å’Œæœ‰æ—¶æ¬£å¿«æ•ˆæœçš„æ–¹å¼è¿…é€Ÿï¼Œç„¶åè¿…é€Ÿä¸‹é™ã€‚ç”±äºå®ƒäº§ç”Ÿçš„[è®°å¿†æŠ‘åˆ¶](../è¯æ•ˆ/home.md)ä¼šå¯¼è‡´ä½¿ç”¨è€…å¿˜è®°ä»–ä»¬å·²ç»æœç”¨è¿‡ï¼Œè¿™å¯èƒ½ä¼šå¯¼è‡´ä¸€ä¸ªå¯¼è‡´å±é™©çš„[å¥å¿˜](../è¯æ•ˆ/home.md)åœç”µçŠ¶æ€çš„å¾ªç¯ï¼Œä»è€Œä½¿æƒ…å†µå˜å¾—æ›´ç³Ÿã€‚
*   **[è®°å¿†æŠ‘åˆ¶](../è¯æ•ˆ/home.md)**
    *   **[å¥å¿˜](../è¯æ•ˆ/home.md)**
*   **[æ¸…é†’é”™è§‰](../è¯æ•ˆ/home.md)** - è¿™æ˜¯ä¸€ç§é”™è¯¯çš„ä¿¡å¿µï¼Œå³å°½ç®¡æœ‰ä¸¥é‡çš„è®¤çŸ¥éšœç¢å’Œæ— æ³•ä¸ä»–äººå……åˆ†äº¤æµç­‰æ˜æ˜¾è¯æ®ï¼Œä½†ä¸€ä¸ªäººä»å®Œå…¨æ¸…é†’ã€‚å®ƒæœ€å¸¸å‘ç”Ÿåœ¨[å¼ºçƒˆ](../è¯æ•ˆ/home.md)åˆ°[ä¸¥é‡](../è¯æ•ˆ/home.md)å‰‚é‡ä¸‹ã€‚
*   **[åˆ†ææŠ‘åˆ¶](../è¯æ•ˆ/home.md)**
*   **[è‡ªæˆ‘è†¨èƒ€](../è¯æ•ˆ/home.md)**
*   **[æ€ç»´å‡é€Ÿ](../è¯æ•ˆ/home.md)**
*   **[åŠ¨æœºæŠ‘åˆ¶](../è¯æ•ˆ/home.md)**
*   **[æƒ…ç»ªæŠ‘åˆ¶](../è¯æ•ˆ/home.md)** - è™½ç„¶è¿™ç§åŒ–åˆç‰©ä¸»è¦æŠ‘åˆ¶ç„¦è™‘ï¼Œä½†å®ƒä¹Ÿä¼šä»¥ä¸€ç§ç‹¬ç‰¹ä½†ä¸å¦‚[æŠ—ç²¾ç¥ç—…è¯](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ—ç²¾ç¥ç—…è¯.md)å¼ºçƒˆçš„æ–¹å¼ä½¿å…¶ä»–æƒ…ç»ªå˜å¾—è¿Ÿé’ã€‚
*   **[å—œç¡](../è¯æ•ˆ/home.md)**

### **è¯æ•ˆæ®‹ä½™**

*   **[åè·³æ€§ç„¦è™‘](../è¯æ•ˆ/home.md)** - åè·³æ€§ç„¦è™‘æ˜¯[ç„¦è™‘ç¼“è§£](../è¯æ•ˆ/home.md)ç‰©è´¨å¦‚[è‹¯äºŒæ°®å“ç±»è¯ç‰©](../æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦/è‹¯äºŒæ°®å“ç±»è¯ç‰©.md)å’Œä¾æ›¿å”‘ä»‘å¸¸è§çš„æ•ˆåº”ã€‚å®ƒé€šå¸¸ä¸åœ¨è¯¥ç‰©è´¨å½±å“ä¸‹èŠ±è´¹çš„æ€»æ—¶é—´ä»¥åŠåœ¨ç»™å®šæœŸé™å†…æ¶ˆè€—çš„æ€»é‡ç›¸å¯¹åº”ï¼Œè¿™ç§æ•ˆåº”å¾ˆå®¹æ˜“å¯¼è‡´ä¾èµ–å’Œæˆç˜¾çš„å¾ªç¯ã€‚
*   **[æ¢¦å¢ƒå¢å¼º](../è¯æ•ˆ/home.md)** æˆ– **[æ¢¦å¢ƒæŠ‘åˆ¶](../è¯æ•ˆ/home.md)**
*   **[æ®‹ç•™å—œç¡](../è¯æ•ˆ/home.md)** - è™½ç„¶ä¾æ›¿å”‘ä»‘å¯ç”¨ä½œæœ‰æ•ˆçš„[åŠ©çœ ](../è¯æ•ˆ/home.md)å‰‚ï¼Œä½†å…¶ä½œç”¨å¯èƒ½ä¼šæŒç»­åˆ°ç¬¬äºŒå¤©æ—©ä¸Šï¼Œè¿™å¯èƒ½å¯¼è‡´ä½¿ç”¨è€…åœ¨å‡ ä¸ªå°æ—¶å†…æ„Ÿåˆ°â€œæ˜æ˜æ²‰æ²‰â€æˆ–â€œè¿Ÿé’â€ã€‚
*   **[æ€ç»´å‡é€Ÿ](../è¯æ•ˆ/home.md)**
*   **[æ€ç»´æ··ä¹±](../è¯æ•ˆ/home.md)**
*   **[æ˜“æ€’](../è¯æ•ˆ/home.md)**

### ä½“éªŒæŠ¥å‘Š

ç›®å‰åœ¨æˆ‘ä»¬çš„[ä½“éªŒç´¢å¼•](../æ–‡æ¡£/å…³äºæœ¬ç«™/home.md)ä¸­æœ‰æè¿°è¯¥åŒ–åˆç‰©æ•ˆåº”çš„è½¶äº‹æŠ¥å‘Šã€‚

*   [Experience:20mg Etizolam - Smoking Etizolam](../æŠ¥å‘Š/psychounautwiki/Experience:20mg_Etizolam_-_Smoking_Etizolam.md)
*   [Experience:2mg Etizolam - Here be dragons](../æŠ¥å‘Š/psychounautwiki/Experience:2mg_Etizolam_-_Here_be_dragons.md)
*   [Experience:3mg Etizolam - A Comedown Drug](../æŠ¥å‘Š/psychounautwiki/Experience:3mg_Etizolam_-_A_Comedown_Drug.md)

å¯ä»¥åœ¨è¿™é‡Œæ‰¾åˆ°æ›´å¤šçš„ä½“éªŒæŠ¥å‘Šï¼š

*   [Erowid Experience Vaults: Etizolam](https://www.erowid.org/experiences/subs/exp_Etizolam.shtml)

## æ¯’æ€§ä¸ä¼¤å®³æ½œåŠ›

![Blepharospasm.png](../æ–‡ä»¶/Blepharospasm.png)

é•¿æœŸä½¿ç”¨å¯èƒ½ä¼šå‘ç”Ÿ[çœ¼ç‘ç—‰æŒ›](http://en.wikipedia.org/wiki/Blepharospasm)ï¼ˆçœ¼çš®æŠ½æï¼‰ã€‚æå°‘æ•°æƒ…å†µä¸‹ï¼Œä¹Ÿæœ‰æŠ¥é“å‡ºç°[ç¦»å¿ƒæ€§ç¯çŠ¶çº¢æ–‘](http://en.wikipedia.org/wiki/Erythema_annulare_centrifugum)çš®è‚¤ç—…å˜ã€‚

æ›´å¤šä¿¡æ¯ï¼š[ç ”ç©¶åŒ–å­¦å“ Â§ æ¯’æ€§ä¸ä¼¤å®³æ½œåŠ›](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/ç ”ç©¶åŒ–å­¦å“.md)

ç›¸å¯¹äºå‰‚é‡ï¼Œä¾æ›¿å”‘ä»‘çš„æ¯’æ€§å¯èƒ½è¾ƒä½ã€‚ç„¶è€Œï¼Œå½“ä¸[é…’ç²¾](../è¯ç‰©/é…’ç²¾.md)æˆ–[é˜¿ç‰‡ç±»è¯ç‰©](../æ–‡æ¡£/è¯ç‰©åº”å¯¹æªæ–½/anti-é˜¿ç‰‡ç±».md)ç­‰[æŠ‘åˆ¶å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md)æ··åˆä½¿ç”¨æ—¶ï¼Œå®ƒå…·æœ‰æ½œåœ¨çš„[è‡´æ­»æ€§](../è¯æ•ˆ/å‘¼å¸æŠ‘åˆ¶.md)ã€‚

å¼ºçƒˆå»ºè®®åœ¨ä½¿ç”¨è¯¥ç‰©è´¨æ—¶é‡‡å–[ä¼¤å®³å‡å°‘æªæ–½](../æ–‡æ¡£/å…³äºæœ¬ç«™/home.md)ï¼Œä¾‹å¦‚[å®¹é‡è®¡é‡](../æ–‡æ¡£/å…³äºæœ¬ç«™/home.md)ã€‚

### è€å—æ€§ä¸æˆç˜¾æ½œåŠ›

åƒå¤§å¤šæ•°è‹¯äºŒæ°®å“ç±»è¯ç‰©ä¸€æ ·ï¼Œä¾æ›¿å”‘ä»‘è¢«è®¤ä¸ºå…·æœ‰é«˜åº¦æˆç˜¾æ€§ï¼Œä¸”æ»¥ç”¨æ½œåŠ›å¾ˆé«˜ã€‚

åœ¨ä¸€é¡¹ç ”ç©¶ä¸­ï¼Œå¯¹å¤§é¼ ç¥ç»å…ƒæ–½ç”¨å¤šå‰‚ä¾æ›¿å”‘ä»‘æˆ–åŠ³æ‹‰è¥¿æ³®ï¼Œè§‚å¯Ÿåˆ°å¯¹åŠ³æ‹‰è¥¿æ³®çš„æŠ—æƒŠå¥ä½œç”¨äº§ç”Ÿè€å—æ€§ï¼Œä½†å¯¹ä¾æ›¿å”‘ä»‘æœªè§‚å¯Ÿåˆ°ã€‚å› æ­¤ï¼Œä¸ç»å…¸è‹¯äºŒæ°®å“ç±»è¯ç‰©ç›¸æ¯”ï¼Œä¾æ›¿å”‘ä»‘è¯±å‘è€å—æ€§å’Œä¾èµ–æ€§çš„å€¾å‘è¾ƒä½ã€‚

ç„¶è€Œï¼Œåœ¨è¿ç»­ä½¿ç”¨å‡ å¤©åï¼Œå¯¹é•‡é™å‚¬çœ ä½œç”¨çš„è€å—æ€§å°†ä¼šå‘å±•ã€‚åœæ­¢ä½¿ç”¨åï¼Œè€å—æ€§ä¼šåœ¨ 7-14 å¤©å†…æ¢å¤åˆ°åŸºçº¿ã€‚ç„¶è€Œï¼Œåœ¨æŸäº›æƒ…å†µä¸‹ï¼Œè¿™å¯èƒ½éœ€è¦æ›´é•¿çš„æ—¶é—´ï¼Œå…·ä½“å–å†³äºé•¿æœŸä½¿ç”¨çš„æŒç»­æ—¶é—´å’Œå¼ºåº¦ã€‚

å¯¹äºé‡åº¦æˆ–é•¿æœŸä½¿ç”¨è€…æ¥è¯´ï¼Œ[å™»å©äºŒæ°®å“ç±»ç‰©è´¨çš„åœç”¨](../æ–‡æ¡£/è¯ç‰©åº”å¯¹æªæ–½/è¯ç‰©æˆ’é™¤/æˆ’æ–­ååº”.md)æ˜¯éå¸¸å›°éš¾çš„ï¼Œå¹¶ä¸”å¯èƒ½å±åŠç”Ÿå‘½ã€‚åœç”¨å™»å©äºŒæ°®å“ç±»ç‰©è´¨åï¼Œç™«ç—«å‘ä½œçš„é£é™©å¢åŠ ã€‚åœ¨ç¨³å®šç»™è¯å‡ å‘¨æˆ–æ›´é•¿æ—¶é—´åçªç„¶åœæ­¢ä½¿ç”¨å¯èƒ½ä¼šå‡ºç°æˆ’æ–­ç—‡çŠ¶æˆ–åè·³ç—‡çŠ¶ï¼Œå¯èƒ½éœ€è¦é€æ¸å‡å°‘å‰‚é‡ã€‚æœ‰å…³ä»¥å—æ§æ–¹å¼ä»å™»å©äºŒæ°®å“ç±»ç‰©è´¨ä¸­é€’å‡çš„æ›´å¤šä¿¡æ¯ï¼Œè¯·å‚é˜…[æœ¬æŒ‡å—](http://www.benzo.org.uk/manual/bzcha02.htm)ã€‚åœ¨æˆ’æ–­æœŸé—´åº”é¿å…ä½¿ç”¨é™ä½ç™«ç—«å‘ä½œé˜ˆå€¼çš„ç‰©è´¨ï¼Œå¦‚[æ›²é©¬å¤š](../è¯ç‰©/æ›²é©¬å¤š.md)ã€‚

ä¾æ›¿å”‘ä»‘ä¸æ‰€æœ‰[è‹¯äºŒæ°®å“ç±»è¯ç‰©](../æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦/è‹¯äºŒæ°®å“ç±»è¯ç‰©.md)å’Œ[å™»å©äºŒæ°®å“ç±»ç‰©è´¨](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å™»å©äºŒæ°®å“ç±»ç‰©è´¨.md)å­˜åœ¨äº¤å‰è€å—æ€§ï¼Œè¿™æ„å‘³ç€åœ¨æœç”¨å®ƒä¹‹åï¼Œæ‰€æœ‰è‹¯äºŒæ°®å“ç±»å’Œå™»å©äºŒæ°®å“ç±»è¯ç‰©çš„æ•ˆæœéƒ½ä¼šé™ä½ã€‚

### è¿‡é‡

å½“å¤§é‡æœç”¨å™»å©äºŒæ°®å“ç±»ç‰©è´¨æˆ–ä¸å…¶ä»–æŠ‘åˆ¶å‰‚åŒæ—¶æœç”¨æ—¶ï¼Œå¯èƒ½ä¼šå‘ç”Ÿè¿‡é‡ã€‚
è¿™ä¸[å·´æ¯”å¦¥ç±»è¯ç‰©](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å·´æ¯”å¦¥ç±».md)å’Œ[é…’ç²¾](../è¯ç‰©/é…’ç²¾.md)ç­‰å…¶ä»– GABA èƒ½æŠ‘åˆ¶å‰‚ä¸€èµ·ä½¿ç”¨æ—¶å°¤å…¶å±é™©ï¼Œå› ä¸ºå®ƒä»¬ä»¥ç±»ä¼¼çš„æ–¹å¼èµ·ä½œç”¨ï¼Œä½†ç»“åˆåœ¨ GABAA å—ä½“ä¸Šä¸åŒçš„å˜æ„ä½ç‚¹ï¼Œå› æ­¤å®ƒä»¬çš„ä½œç”¨ç›¸äº’å¢å¼ºã€‚
å™»å©äºŒæ°®å“ç±»è¯ç‰©å¢åŠ äº† GABAA å—ä½“ä¸Šæ°¯ç¦»å­å­”å¼€æ”¾çš„é¢‘ç‡ï¼Œè€Œå·´æ¯”å¦¥ç±»è¯ç‰©å¢åŠ äº†å®ƒä»¬å¼€æ”¾çš„æŒç»­æ—¶é—´ï¼Œè¿™æ„å‘³ç€å½“ä¸¤è€…åŒæ—¶æœç”¨æ—¶ï¼Œç¦»å­å­”å°†æ›´é¢‘ç¹åœ°å¼€æ”¾å¹¶ä¿æŒå¼€æ”¾æ›´é•¿æ—¶é—´ã€‚
å™»å©äºŒæ°®å“ç±»è¯ç‰©è¿‡é‡æ˜¯ä¸€ç§åŒ»ç–—ç´§æ€¥æƒ…å†µï¼Œå¦‚æœä¸åŠæ—¶å’Œå¦¥å–„æ²»ç–—ï¼Œå¯èƒ½å¯¼è‡´æ˜è¿·ã€æ°¸ä¹…æ€§è„‘æŸä¼¤æˆ–æ­»äº¡ã€‚

å™»å©äºŒæ°®å“ç±»è¯ç‰©è¿‡é‡çš„ç—‡çŠ¶å¯èƒ½åŒ…æ‹¬ä¸¥é‡çš„[æ€ç»´å‡é€Ÿ](../è¯æ•ˆ/home.md)ã€[è¨€è¯­ä¸æ¸…](../è¯æ•ˆ/home.md)ã€[æ„è¯†æ¨¡ç³Š](../è¯æ•ˆ/home.md)ã€[å¦„æƒ³](../è¯æ•ˆ/home.md)ã€[å‘¼å¸æŠ‘åˆ¶](../è¯æ•ˆ/å‘¼å¸æŠ‘åˆ¶.md)ã€æ˜è¿·æˆ–æ­»äº¡ã€‚
å™»å©äºŒæ°®å“ç±»è¯ç‰©è¿‡é‡å¯ä»¥åœ¨åŒ»é™¢ç¯å¢ƒä¸­å¾—åˆ°æœ‰æ•ˆæ²»ç–—ï¼Œç»“æœé€šå¸¸è‰¯å¥½ã€‚
å™»å©äºŒæ°®å“ç±»è¯ç‰©è¿‡é‡æœ‰æ—¶ç”¨[æ°Ÿé©¬è¥¿å°¼](../è¯ç‰©/æ°Ÿé©¬è¥¿å°¼.md)æ²»ç–—ï¼Œè¿™æ˜¯ä¸€ç§ GABAA æ‹®æŠ—å‰‚ã€‚ç„¶è€Œï¼ŒæŠ¤ç†ä¸»è¦æ˜¯æ”¯æŒæ€§çš„ã€‚

### å±é™©çš„è¯ç‰©è”ç”¨

***è­¦å‘Šï¼š*** *è®¸å¤šå•ç‹¬ä½¿ç”¨ç›¸å½“å®‰å…¨çš„ç²¾ç¥æ´»æ€§ç‰©è´¨ï¼Œå½“ä¸æŸäº›å…¶ä»–ç‰©è´¨ç»“åˆä½¿ç”¨æ—¶ï¼Œå¯èƒ½ä¼šçªç„¶å˜å¾—å±é™©ç”šè‡³å±åŠç”Ÿå‘½ã€‚ä»¥ä¸‹åˆ—è¡¨åˆ—å‡ºäº†ä¸€äº›å·²çŸ¥çš„å±é™©ç›¸äº’ä½œç”¨ï¼ˆå°½ç®¡ä¸ä¿è¯åŒ…æ‹¬æ‰€æœ‰ç›¸äº’ä½œç”¨ï¼‰ã€‚*

*è¯·åŠ¡å¿…è¿›è¡Œç‹¬ç«‹ç ”ç©¶ï¼ˆä¾‹å¦‚ [Google](https://www.google.com)ã€[DuckDuckGo](https://www.duckduckgo.com)ã€[PubMed](https://pubmed.ncbi.nlm.nih.gov/)ï¼‰ä»¥ç¡®ä¿ä¸¤ç§æˆ–å¤šç§ç‰©è´¨çš„ç»„åˆå¯ä»¥å®‰å…¨é£Ÿç”¨ã€‚éƒ¨åˆ†åˆ—å‡ºçš„ç›¸äº’ä½œç”¨æ¥è‡ª [TripSit](https://combo.tripsit.me)ã€‚*

*   â›” **[æŠ‘åˆ¶å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md)** (*[1,4-ä¸äºŒé†‡](../è¯ç‰©/1,4-ä¸äºŒé†‡.md), [2-ç”²åŸº-2-ä¸é†‡](../è¯ç‰©/2-ç”²åŸº-2-ä¸é†‡.md), [é…’ç²¾](../è¯ç‰©/é…’ç²¾.md), [å·´æ¯”å¦¥ç±»](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å·´æ¯”å¦¥ç±».md), [GHB](../è¯ç‰©/GHB.md)/[GBL](../è¯ç‰©/GBL.md), [ç”²å–¹é…®](../è¯ç‰©/ç”²å–¹é…®.md), [é˜¿ç‰‡ç±»](../æ–‡æ¡£/è¯ç‰©åº”å¯¹æªæ–½/anti-é˜¿ç‰‡ç±».md)*) - è¿™ç§ç»„åˆå¯èƒ½å¯¼è‡´å±é™©ç”šè‡³è‡´å‘½æ°´å¹³çš„[å‘¼å¸æŠ‘åˆ¶](../è¯æ•ˆ/å‘¼å¸æŠ‘åˆ¶.md)ã€‚è¿™äº›ç‰©è´¨ä¼šå¢å¼ºå½¼æ­¤å¼•èµ·çš„[è‚Œè‚‰æ¾å¼›](../è¯æ•ˆ/è‚Œè‚‰æ¾å¼›.md)ã€[é•‡é™](../è¯æ•ˆ/é•‡é™.md)å’Œ[å¥å¿˜](../è¯æ•ˆ/home.md)ï¼Œå¹¶å¯èƒ½åœ¨é«˜å‰‚é‡ä¸‹å¯¼è‡´æ„å¤–çš„æ„è¯†ä¸§å¤±ã€‚åœ¨æ— æ„è¯†æœŸé—´å‘•åå’Œå› çª’æ¯è€Œæ­»äº¡çš„é£é™©ä¹Ÿä¼šå¢åŠ ã€‚å¦‚æœå‘ç”Ÿè¿™ç§æƒ…å†µï¼Œä½¿ç”¨è€…åº”å°è¯•ä»¥[å¤è‹ä½“ä½](../æ–‡æ¡£/è¯ç‰©åº”å¯¹æªæ–½/BLSï¼ˆåŸºæœ¬ç”Ÿå‘½ç»´æŒæœ¯ï¼‰.md)å…¥ç¡ï¼Œæˆ–è®©æœ‹å‹å°†ä»–ä»¬ç§»è‡³è¯¥ä½“ä½ã€‚
*   ğŸ’” **[è§£ç¦»å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è§£ç¦»å‰‚.md)** - è¿™ç§ç»„åˆå¯èƒ½å¯¼è‡´åœ¨æ— æ„è¯†æœŸé—´å‘•åå’Œå› çª’æ¯è€Œæ­»äº¡çš„é£é™©å¢åŠ ã€‚å¦‚æœå‘ç”Ÿè¿™ç§æƒ…å†µï¼Œä½¿ç”¨è€…åº”å°è¯•ä»¥[å¤è‹ä½“ä½](../æ–‡æ¡£/è¯ç‰©åº”å¯¹æªæ–½/BLSï¼ˆåŸºæœ¬ç”Ÿå‘½ç»´æŒæœ¯ï¼‰.md)å…¥ç¡ï¼Œæˆ–è®©æœ‹å‹å°†ä»–ä»¬ç§»è‡³è¯¥ä½“ä½ã€‚
*   âš ï¸ **[å…´å¥‹å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)** - å°†å™»å©äºŒæ°®å“ç±»ç‰©è´¨ä¸[å…´å¥‹å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)ç»“åˆä½¿ç”¨æ˜¯å±é™©çš„ï¼Œå› ä¸ºå­˜åœ¨è¿‡åº¦ä¸­æ¯’çš„é£é™©ã€‚å…´å¥‹å‰‚æ©ç›–äº†å™»å©äºŒæ°®å“ç±»ç‰©è´¨çš„[é•‡é™](../è¯æ•ˆ/é•‡é™.md)ä½œç”¨ï¼Œè¿™æ˜¯å¤§å¤šæ•°äººåœ¨ç¡®å®šå…¶ä¸­æ¯’ç¨‹åº¦æ—¶è€ƒè™‘çš„ä¸»è¦å› ç´ ã€‚ä¸€æ—¦å…´å¥‹å‰‚æ¶ˆé€€ï¼Œå™»å©äºŒæ°®å“ç±»ç‰©è´¨çš„ä½œç”¨å°†æ˜¾è‘—å¢åŠ ï¼Œå¯¼è‡´å¼ºåŒ–çš„[å»æŠ‘åˆ¶](../è¯æ•ˆ/home.md)ã€‚å¦‚æœç»“åˆä½¿ç”¨ï¼Œåº”ä¸¥æ ¼é™åˆ¶æ¯å°æ—¶åªæœç”¨ä¸€å®šé‡çš„å™»å©äºŒæ°®å“ç±»ç‰©è´¨ã€‚å¦‚æœæœªç›‘æµ‹æ°´åˆ†è¡¥å……ï¼Œè¿™ç§ç»„åˆä¹Ÿå¯èƒ½å¯¼è‡´ä¸¥é‡è„±æ°´ã€‚

## æ³•å¾‹åœ°ä½

åœ¨å›½é™…ä¸Šï¼Œä¾æ›¿å”‘ä»‘äº 2020 å¹´ 3 æœˆè¢«åˆ—å…¥è”åˆå›½ç²¾ç¥è¯ç‰©å…¬çº¦ä½œä¸ºé™„è¡¨ IV ç®¡åˆ¶ç‰©è´¨ã€‚

*   **æ¾³å¤§åˆ©äºš**ï¼šç”±è¯ç‰©ç®¡åˆ¶åŠå…¬å®¤æ ¹æ® 1956 å¹´æµ·å…³ï¼ˆç¦æ­¢è¿›å£ï¼‰æ¡ä¾‹ç¬¬ 5 æ¡å‘å¸ƒçš„é™„è¡¨ 4ã€‚2020 å¹´ 10 æœˆçš„æ¯’è¯æ ‡å‡†ä¸­æœªè¯´æ˜å…¶ä¸ºé™„è¡¨ 4ï¼Œä½†å¯èƒ½æ ¹æ®ç±»ä¼¼ç‰©æ³•æ¡ˆä½œä¸ºå»æ°¯ä¾æ›¿å”‘ä»‘å½’ç±»ã€‚è¿›å‡ºå£éœ€è¦è®¸å¯è¯å’Œè®¸å¯ã€‚
*   **å¥¥åœ°åˆ©**ï¼šè‡ª 2012 å¹´èµ·ï¼Œæ ¹æ® NPSG (*Neue Psychoaktive Substanzen Gesetz*)ï¼Œæ‹¥æœ‰ã€ç”Ÿäº§ã€ä¾›åº”æˆ–è¿›å£ä¾æ›¿å”‘ä»‘æ˜¯éæ³•çš„ã€‚ä½†æ˜¯ï¼Œæ²¡æœ‰åˆ†é”€æ„å›¾çš„è¿æ³•è€…å¯èƒ½ä¸ä¼šé¢ä¸´æŒ‡æ§ã€‚
*   **å·´è¥¿**ï¼šè‡ª 2021 å¹´ 3 æœˆ 23 æ—¥èµ·ï¼Œæ ¹æ® ANVISA çš„å†³è®® RDC nÂº 473ï¼Œç”±äºå…¶åˆ—åœ¨ Portaria SVS/MS nÂº 344 ä¸Šï¼Œæ‹¥æœ‰ã€ç”Ÿäº§å’Œé”€å”®æ˜¯éæ³•çš„ã€‚
*   **åŠ æ‹¿å¤§**ï¼šä¾æ›¿å”‘ä»‘ä¼¼ä¹è¢« CDSA é™„è¡¨ VI ç¬¬ 18 æ¡ä½œä¸ºâ€œè‹¯äºŒæ°®å“ç±»åŠå…¶ç›ç±»å’Œè¡ç”Ÿç‰©â€æ•è·ã€‚
*   **å¾·å›½**ï¼šæˆªè‡³ 2013 å¹´ 7 æœˆ 17 æ—¥ï¼Œä¾æ›¿å”‘ä»‘å— Anlage III BtMGï¼ˆ*éº»é†‰å“æ³•ï¼Œé™„è¡¨ III*ï¼‰ç®¡åˆ¶ã€‚å®ƒåªèƒ½é€šè¿‡éº»é†‰å“å¤„æ–¹å•å¼€å…·å¤„æ–¹ã€‚
*   **æ—¥æœ¬**ï¼šä¾æ›¿å”‘ä»‘åœ¨æ—¥æœ¬å—éº»é†‰å“å’Œç²¾ç¥è¯ç‰©ç®¡åˆ¶æ³•ç®¡åˆ¶ï¼Œæœªç»å¤„æ–¹æ‹¥æœ‰ã€é”€å”®æˆ–åˆ¶é€ æ˜¯éæ³•çš„ã€‚
*   **æ³¢å…°**ï¼šä¾æ›¿å”‘ä»‘åœ¨æ³¢å…°æ˜¯ NPS ç±»è¯ç‰©ï¼Œæ‹¥æœ‰æˆ–åˆ†é”€æ˜¯éæ³•çš„ã€‚
*   **ä¿„ç½—æ–¯**ï¼šåœ¨ä¿„ç½—æ–¯ï¼Œè‡ª 2017 å¹´èµ·ï¼Œä¾æ›¿å”‘ä»‘æ˜¯é™„è¡¨ III ç®¡åˆ¶ç‰©è´¨ã€‚
*   **ç‘å£«**ï¼šä¾æ›¿å”‘ä»‘æ˜¯åœ¨ Verzeichnis B ä¸‹ç‰¹åˆ«å‘½åçš„ç®¡åˆ¶ç‰©è´¨ã€‚å…è®¸è¯ç”¨ã€‚
*   **åœŸè€³å…¶**ï¼šä¾æ›¿å”‘ä»‘è¢«å½’ç±»ä¸ºè¯ç‰©ï¼Œæ‹¥æœ‰ã€ç”Ÿäº§ã€ä¾›åº”æˆ–è¿›å£æ˜¯éæ³•çš„ã€‚
*   **è·å…°**ï¼šä¾æ›¿å”‘ä»‘æ˜¯é¸¦ç‰‡æ³•æ¸…å• 2 ç‰©è´¨ï¼Œä½¿å…¶éæ³•ã€‚
*   **è‹±å›½**ï¼šæˆªè‡³ 2017 å¹´ 5 æœˆ 31 æ—¥ï¼Œä¾æ›¿å”‘ä»‘åœ¨è‹±å›½æ˜¯ C ç±»ç‰©è´¨ï¼Œæ‹¥æœ‰ã€ç”Ÿäº§æˆ–ä¾›åº”æ˜¯éæ³•çš„ã€‚
*   **ç¾å›½**ï¼šä¾æ›¿å”‘ä»‘äº 2023 å¹´ 1 æœˆ 23 æ—¥è¢« DEA ä¸´æ—¶åˆ—ç®¡ï¼Œä½¿ä¾æ›¿å”‘ä»‘æˆä¸ºé™„è¡¨ I ç®¡åˆ¶ç‰©è´¨ã€‚åœ¨å…¶ä¸´æ—¶åˆ—ç®¡ä¹‹å‰ï¼Œä¸€äº›å·ç«‹æ³•æœºæ„å·²é€šè¿‡æ³•å¾‹åœ¨å…¶ç®¡è¾–èŒƒå›´å†…ç¦æ­¢è¯¥ç‰©è´¨ã€‚æˆªè‡³ 2019 å¹´ 7 æœˆï¼Œä¾æ›¿å”‘ä»‘åœ¨ä»¥ä¸‹å·æ˜¯ç®¡åˆ¶ç‰©è´¨ï¼šé˜¿æ‹‰å·´é©¬å·ã€é˜¿è‚¯è‰²å·ã€ä½›ç½—é‡Œè¾¾å·ã€ä½æ²»äºšå·ã€è·¯æ˜“æ–¯å®‰é‚£å·ã€å¯†è¥¿è¥¿æ¯”å·ã€å¾—å…‹è¨æ–¯å·ã€å—å¡ç½—æ¥çº³å·å’Œå¼—å‰å°¼äºšå·ã€å°ç¬¬å®‰çº³å·å’Œä¿„äº¥ä¿„å·ã€‚
    *   **äºšåˆ©æ¡‘é‚£å·ï¼š** 2018 å¹´ï¼Œäºšåˆ©æ¡‘é‚£å·ç«‹æ³•æœºæ„æ ¹æ®ä¼—è®®é™¢ç¬¬ 2033 å·æ³•æ¡ˆå°†ä¾æ›¿å”‘ä»‘åˆ—ä¸ºç®¡åˆ¶ç‰©è´¨ã€‚
    *   **é˜¿è‚¯è‰²å·ï¼š** 2014 å¹´ 8 æœˆï¼Œé˜¿è‚¯è‰²å·æ ¹æ®å…¶ç‰©è´¨è°ƒåº¦æŒ‡å—å°†ä¾æ›¿å”‘ä»‘åˆ—ä¸ºé™„è¡¨ I ç‰©è´¨ã€‚
    *   **åŒ—å¡ç½—æ¥çº³å·ï¼š** 2017 å¹´ 3 æœˆ 22 æ—¥ï¼ŒåŒ—å¡ç½—æ¥çº³å·è®®ä¼šé¢å¸ƒäº†åŒ—å¡ç½—æ¥çº³å·ç®¡åˆ¶ç‰©è´¨æ³•çš„é™„å½•ï¼Œå°†ä¾æ›¿å”‘ä»‘åˆ—ä¸ºé™„è¡¨ I ç‰©è´¨ã€‚
    *   **å¾—å…‹è¨æ–¯å·ï¼š** 2017 å¹´ 6 æœˆ 9 æ—¥ï¼Œå¾—å…‹è¨æ–¯å·é€šè¿‡ HB 2671 å°†ä¾æ›¿å”‘ä»‘åˆ—ä¸ºæƒ©ç½šç»„ 3 ç‰©è´¨ã€‚ä¸ä¸€äº›åœ¨çº¿æŠ¥å‘Šå’Œæ•´ä¸ªå¾—å…‹è¨æ–¯å·ç®¡åˆ¶ç‰©è´¨æ¸…å•ç½‘ç«™çš„å†²çªä¿¡æ¯ç›¸åï¼Œéšç€è¯¥æ³•æ¡ˆçš„é€šè¿‡ï¼Œä¾æ›¿å”‘ä»‘æˆä¸ºæƒ©ç½šç»„ 3 ç‰©è´¨ã€‚
*   **ä¸­å›½**ï¼šä¾æ›¿å”‘ä»‘åœ¨ä¸­å›½è¢«åˆ—ä¸ºç¬¬äºŒç±»ç²¾ç¥è¯å“è¿›è¡Œç®¡åˆ¶ã€‚

## å¦è§

*   [ä¼¤å®³å‡å°‘æªæ–½](../æ–‡æ¡£/å…³äºæœ¬ç«™/home.md)
    *   [å®¹é‡è®¡é‡](../æ–‡æ¡£/å…³äºæœ¬ç«™/home.md)
*   [æŠ‘åˆ¶å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md)
*   [è‹¯äºŒæ°®å“ç±»è¯ç‰©](../æ–‡æ¡£/ç²¾ç¥è¯ç†å­¦/è‹¯äºŒæ°®å“ç±»è¯ç‰©.md)
*   [äºŒæ°¯è¥¿æ³®](../è¯ç‰©/äºŒæ°¯è¥¿æ³®.md)
*   [é˜¿æ™®å”‘ä»‘](./é˜¿æ™®å”‘ä»‘.md)
*   [é…’ç²¾](../è¯ç‰©/é…’ç²¾.md)

## å¤–éƒ¨é“¾æ¥

*   [Etizolam (Wikipedia)](http://en.wikipedia.org/wiki/Etizolam)
*   [Etizolam (Erowid Vault)](http://www.erowid.org/pharms/etizolam)
*   [Etizolam (Isomer Design)](https://isomerdesign.com/PiHKAL/explore.php?id=3039)
*   [Etizolam (Drugs-Forum)](https://drugs-forum.com/wiki/Etizolam)

## æ–‡çŒ®

*   Sanna, E., Pau, D., Tuveri, F., Massa, F., Maciocco, E., Acquas, C., ... & Biggio, G. (1999). Molecular and neurochemical evaluation of the effects of etizolam on GABAA receptors under normal and stress conditions. Arzneimittelforschung, 49(02), 88-95. https://doi.org/10.1055/s-0031-1300366
*   Altamura, A. C., Moliterno, D., Paletta, S., Maffini, M., Mauri, M. C., & Bareggi, S. (2013). Understanding the pharmacokinetics of anxiolytic drugs. Expert Opinion on Drug Metabolism & Toxicology, 9(4), 423-440. https://doi.org/10.1517/17425255.2013.759209
*   Fracasso, C., Confalonieri, S., Garattini, S., & Caccia, S. (1991). Single and multiple dose pharmacokinetics of etizolam in healthy subjects. European Journal of Clinical Pharmacology, 40(2), 181-185. https://doi.org/10.1007/BF00280074

## å‚è€ƒèµ„æ–™

1.  [â†‘](#cite_ref-tripsit_1-0) [*Risks of Combining Depressants - TripSit*](https://tripsit.me/combining-depressants/)
2.  [â†‘](#cite_ref-2) Kahan, M., Wilson, L., Mailis-Gagnon, A., Srivastava, A. (November 2011). ["Canadian guideline for safe and effective use of opioids for chronic noncancer pain. Appendix B-6: Benzodiazepine Tapering"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3215603/). *Canadian Family Physician*. **57** (11): 1269â€“1276. [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [0008-350X](//www.worldcat.org/issn/0008-350X).
3.  [â†‘](#cite_ref-3) [*Etizolam - TripSit wiki*](https://wiki.tripsit.me/wiki/Etizolam), retrieved 11 May 2017
4.  [â†‘](#cite_ref-Sanna2011_4-0) Sanna, E., Pau, D., Tuveri, F., Massa, F., Maciocco, E., Acquas, C., Floris, C., Fontana, S., Maira, G., Biggio, G. (28 December 2011). ["Molecular and Neurochemical Evaluation of the Effects of Etizolam on GABAA Receptors under Normal and Stress Conditions"](http://www.thieme-connect.de/DOI/DOI?10.1055/s-0031-1300366). *Arzneimittelforschung*. **49** (02): 88â€“95. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1055/s-0031-1300366](//doi.org/10.1055%2Fs-0031-1300366). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [0004-4172](//www.worldcat.org/issn/0004-4172).
5.  [â†‘](#cite_ref-5) Haefely, W. (29 June 1984). "Benzodiazepine interactions with GABA receptors". *Neuroscience Letters*. **47** (3): 201â€“206. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/0304-3940(84)90514-7](//doi.org/10.1016%2F0304-3940%2884%2990514-7). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [0304-3940](//www.worldcat.org/issn/0304-3940).
6.  [â†‘](#cite_ref-6) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3684331/#s2title
7.  [â†‘](#cite_ref-7) SaÃ¯as, T., Gallarda, T. (September 2008). "[Paradoxical aggressive reactions to benzodiazepine use: a review]". *Lâ€™Encephale*. **34** (4): 330â€“336. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/j.encep.2007.05.005](//doi.org/10.1016%2Fj.encep.2007.05.005). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [0013-7006](//www.worldcat.org/issn/0013-7006).
8.  [â†‘](#cite_ref-8) Paton, C. (December 2002). ["Benzodiazepines and disinhibition: a review"](https://www.cambridge.org/core/journals/psychiatric-bulletin/article/benzodiazepines-and-disinhibition-a-review/421AF197362B55EDF004700452BF3BC6). *Psychiatric Bulletin*. **26** (12): 460â€“462. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1192/pb.26.12.460](//doi.org/10.1192%2Fpb.26.12.460). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [0955-6036](//www.worldcat.org/issn/0955-6036).
9.  [â†‘](#cite_ref-9) Bond, A. J. (1 January 1998). ["Drug- Induced Behavioural Disinhibition"](https://doi.org/10.2165/00023210-199809010-00005). *CNS Drugs*. **9** (1): 41â€“57. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.2165/00023210-199809010-00005](//doi.org/10.2165%2F00023210-199809010-00005). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [1179-1934](//www.worldcat.org/issn/1179-1934).
10. [â†‘](#cite_ref-10) Drummer, O. H. (February 2002). "Benzodiazepines - Effects on Human Performance and Behavior". *Forensic Science Review*. **14** (1â€“2): 1â€“14. [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [1042-7201](//www.worldcat.org/issn/1042-7201).
11. [â†‘](#cite_ref-11) Wakakura, M., Tsubouchi, T., Inouye, J. (March 2004). "Etizolam and benzodiazepine induced blepharospasm". *Journal of Neurology, Neurosurgery, and Psychiatry*. **75** (3): 506â€“507. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1136/jnnp.2003.019869](//doi.org/10.1136%2Fjnnp.2003.019869). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [0022-3050](//www.worldcat.org/issn/0022-3050).
12. [â†‘](#cite_ref-12) Kuroda, K., Yabunami, H., Hisanaga, Y. (January 2002). "Etizolam-induced superficial erythema annulare centrifugum". *Clinical and Experimental Dermatology*. **27** (1): 34â€“36. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1046/j.0307-6938.2001.00943.x](//doi.org/10.1046%2Fj.0307-6938.2001.00943.x). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [0307-6938](//www.worldcat.org/issn/0307-6938).
13. [â†‘](#cite_ref-13) Mandrioli, R., Mercolini, L., Raggi, M. A. (October 2008). "Benzodiazepine metabolism: an analytical perspective". *Current Drug Metabolism*. **9** (8): 827â€“844. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.2174/138920008786049258](//doi.org/10.2174%2F138920008786049258). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [1389-2002](//www.worldcat.org/issn/1389-2002).
14. â†‘ [14.0](#cite_ref-thirteen_14-0) [14.1](#cite_ref-thirteen_14-1) Sanna, E., Busonero, F., Talani, G., Mostallino, M. C., Mura, M. L., Pisu, M. G., Maciocco, E., Serra, M., Biggio, G. (5 September 2005). "Low tolerance and dependence liabilities of etizolam: molecular, functional, and pharmacological correlates". *European Journal of Pharmacology*. **519** (1â€“2): 31â€“42. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/j.ejphar.2005.06.047](//doi.org/10.1016%2Fj.ejphar.2005.06.047). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [0014-2999](//www.worldcat.org/issn/0014-2999).
15. [â†‘](#cite_ref-15) Twyman, R. E., Rogers, C. J., Macdonald, R. L. (March 1989). "Differential regulation of gamma-aminobutyric acid receptor channels by diazepam and phenobarbital". *Annals of Neurology*. **25** (3): 213â€“220. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1002/ana.410250302](//doi.org/10.1002%2Fana.410250302). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [0364-5134](//www.worldcat.org/issn/0364-5134).
16. [â†‘](#cite_ref-16) Hoffman, E. J., Warren, E. W. (September 1993). "Flumazenil: a benzodiazepine antagonist". *Clinical Pharmacy*. **12** (9): 641â€“656; quiz 699â€“701. [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [0278-2677](//www.worldcat.org/issn/0278-2677).
17. [â†‘](#cite_ref-17) ["WHO: World Health Organization recommends 12 NPS for scheduling"](https://www.unodc.org/LSS/Announcement/Details/021820a0-8746-42a4-9ee3-47ce50b30ca3). December 2019. Retrieved October 16, 2020.
18. [â†‘](#cite_ref-18) ["CND accepts all WHO recommendations on the control of several psychoactive substances from the 42nd ECDD meeting"](https://www.who.int/news/item/18-03-2020-c-n-d-accepts-all-w-h-o-recommendations-from-42nd-e-c-d-d). World Health Organization (WHO). March 18, 2020. Retrieved October 16, 2020.
19. [â†‘](#cite_ref-19) Health, [*Poisons Standard October 2020*](http://www.legislation.gov.au/Details/F2020L01255/Html/Text)
20. [â†‘](#cite_ref-20) ["Neue Psychoaktive Substanzen"](https://www.oesterreich.gv.at/themen/gesundheit_und_notfaelle/sucht/2/1/Seite.1520660.html) (in German). Bundeskriminalamt Ã–sterreich. Retrieved February 17, 2022.
21. [â†‘](#cite_ref-21) ["NPSG"](https://www.ris.bka.gv.at/GeltendeFassung.wxe?Abfrage=Bundesnormen&Gesetzesnummer=20007605) (in German). Bundeskriminalamt Ã–sterreich. Retrieved February 17, 2022.
22. [â†‘](#cite_ref-22) ["ResoluÃ§Ã£o de diretoria colegiada - RDC NÂº 473"](http://antigo.anvisa.gov.br/documents/10181/6236630/%282%29RDC_473_2021_.pdf/7a65445f-52a1-4533-97c7-6d96eff3b8e1) (in Portuguese). Retrieved May 20, 2021.
23. [â†‘](#cite_ref-23) ["Portaria SVS/MS nÂº 344 - Lista de substÃ¢ncias sujeitas a controle especial no Brasil"](https://web.archive.org/web/20210520204528/https://www.gov.br/anvisa/pt-br/assuntos/medicamentos/controlados/lista-substancias) (in Portuguese). Retrieved May 20, 2021.
24. [â†‘](#cite_ref-24) ["Anlage III BtMG"](https://www.gesetze-im-internet.de/btmg_1981/anlage_iii.html) (in German). Bundesministerium der Justiz und fÃ¼r Verbraucherschutz. Retrieved December 19, 2019.
25. [â†‘](#cite_ref-25) ["Siebenundzwanzigste Verordnung zur Ã„nderung betÃ¤ubungsmittelrechtlicher Vorschriften"](https://www.bgbl.de/xaver/bgbl/start.xav#__bgbl__//*%5B@attr_id=%27bgbl113s2274.pdf%27%5D) (in German). Bundesanzeiger Verlag. Retrieved December 19, 2019.
26. [â†‘](#cite_ref-26) ["Â§ 8 BtMVV"](https://www.gesetze-im-internet.de/btmvv_1998/__8.html) (in German). Bundesministerium der Justiz und fÃ¼r Verbraucherschutz. Retrieved December 19, 2019.
27. [â†‘](#cite_ref-27) ["æ–°ãŸã«ï¼“ç‰©è³ªã‚’å‘ç²¾ç¥è–¬ã«æŒ‡å®šã—ã¾ã™"](https://www.mhlw.go.jp/seisakunitsuite/bunya/kenkou_iryou/iyakuhin/yakubuturanyou/oshirase/20160914-1.html) (in Japanese). åšç”ŸåŠ´åƒçœ [Ministry of Health, Labour and Welfare (MHLW)]. Retrieved March 28, 2021.
28. [â†‘](#cite_ref-28) ["RozporzÄ…dzenie Ministra zdrowia z dnia 21 sierpnia 2019 r. zmieniajÄ…ce rozporzÄ…dzenie w sprawie wykazu substancji psychotropowych, Å›rodkÃ³w odurzajÄ…cych oraz nowych substancji psychoaktywnych"](http://prawo.sejm.gov.pl/isap.nsf/download.xsp/WDU20190001745/O/D20191745.pdf) (PDF) (in Polish).
29. [â†‘](#cite_ref-29) [*ĞŸĞ¾ÑÑ‚Ğ°Ğ½Ğ¾Ğ²Ğ»ĞµĞ½Ğ¸Ğµ ĞŸÑ€Ğ°Ğ²Ğ¸Ñ‚ĞµĞ»ÑŒÑÑ‚Ğ²Ğ° Ğ Ğ¤ Ğ¾Ñ‚ 12.07.2017 N 827 â€œĞ Ğ²Ğ½ĞµÑĞµĞ½Ğ¸Ğ¸ Ğ¸Ğ·Ğ¼ĞµĞ½ĞµĞ½Ğ¸Ğ¹ Ğ² Ğ½ĞµĞºĞ¾Ñ‚Ğ¾Ñ€Ñ‹Ğµ Ğ°ĞºÑ‚Ñ‹ ĞŸÑ€Ğ°Ğ²Ğ¸Ñ‚ĞµĞ»ÑŒÑÑ‚Ğ²Ğ° Ğ Ğ¾ÑÑĞ¸Ğ¹ÑĞºĞ¾Ğ¹ Ğ¤ĞµĞ´ĞµÑ€Ğ°Ñ†Ğ¸Ğ¸ Ğ² ÑĞ²ÑĞ·Ğ¸ Ñ ÑĞ¾Ğ²ĞµÑ€ÑˆĞµĞ½ÑÑ‚Ğ²Ğ¾Ğ²Ğ°Ğ½Ğ¸ĞµĞ¼ ĞºĞ¾Ğ½Ñ‚Ñ€Ğ¾Ğ»Ñ Ğ·Ğ° Ğ¾Ğ±Ğ¾Ñ€Ğ¾Ñ‚Ğ¾Ğ¼ Ğ½Ğ°Ñ€ĞºĞ¾Ñ‚Ğ¸Ñ‡ĞµÑĞºĞ¸Ñ… ÑÑ€ĞµĞ´ÑÑ‚Ğ² Ğ¸ Ğ¿ÑĞ¸Ñ…Ğ¾Ñ‚Ñ€Ğ¾Ğ¿Ğ½Ñ‹Ñ… Ğ²ĞµÑ‰ĞµÑÑ‚Ğ²â€ - ĞšĞ¾Ğ½ÑÑƒĞ»ÑŒÑ‚Ğ°Ğ½Ñ‚ĞŸĞ»ÑÑ*](https://www.consultant.ru/cons/cgi/online.cgi?req=doc&base=LAW&n=220067&dst=1000000001&date=02.12.2019)
30. [â†‘](#cite_ref-30) ["Verordnung des EDI Ã¼ber die Verzeichnisse der BetÃ¤ubungsmittel, psychotropen Stoffe, VorlÃ¤uferstoffe und Hilfschemikalien"](https://www.admin.ch/opc/de/classified-compilation/20101220/index.html) (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.
31. [â†‘](#cite_ref-Bakanlar_Kurulu_Karar.C4.B1_-_Karar_Say.C4.B1s.C4.B1_:_2013.2F5742_31-0) [*BaÅŸbakanlÄ±k MevzuatÄ± GeliÅŸtirme ve YayÄ±n Genel MÃ¼dÃ¼rlÃ¼ÄŸÃ¼*](https://resmigazete.gov.tr/eskiler/2014/01/20140125-3.htm)
32. [â†‘](#cite_ref-List_of_illegal_substances_for_law_32-0) https://resmigazete.gov.tr/eskiler/2014/01/20140125-3-1.pdf
33. [â†‘](#cite_ref-33) [*Opiumwet, Lijst II (Dutch)*](https://wetten.overheid.nl/BWBR0001941/2023-09-12#BijlageII), 2023
34. [â†‘](#cite_ref-34) The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2017 | http://www.tihs.org.uk/timeline/resources/2017-631.pdf
35. [â†‘](#cite_ref-35) Schedules of Controlled Substances: Temporary Placement of Etizolam, Flualprazolam, Clonazolam, Flubromazolam, and Diclazepam in Schedule I | https://www.federalregister.gov/documents/2022/12/23/2022-27278/schedules-of-controlled-substances-temporary-placement-of-etizolam-flualprazolam-clonazolam
36. [â†‘](#cite_ref-36) [*Alabama Code Title 20. Food, Drugs, and Cosmetics Â§ 20-2-23*](https://codes.findlaw.com/al/title-20-food-drugs-and-cosmetics/al-code-sect-20-2-23.html)
37. [â†‘](#cite_ref-37) http://www.healthy.arkansas.gov/aboutadh/rulesregs/controlled_substances_list.pdf
38. [â†‘](#cite_ref-38) [*Statutes & Constitution :View Statutes : Online Sunshine*](http://www.leg.state.fl.us/Statutes/index.cfm?App_mode=Display_Statute&URL=0800-0899/0893/Sections/0893.03.html)
39. [â†‘](#cite_ref-39) http://www.namsdl.org/library/946E60B2-ABB3-24A6-F087859B3EA48EC1/
40. [â†‘](#cite_ref-40) [*HB1231 (As Sent to Governor) - 2014 Regular Session*](http://billstatus.ls.state.ms.us/documents/2014/html/HB/1200-1299/HB1231SG.htm)
41. [â†‘](#cite_ref-41) [*Controlled Substance Schedule, SCDHEC*](https://scdhec.gov/healthcare-quality/drug-control-register-verify/controlled-substance-schedule)
42. [â†‘](#cite_ref-42) [*18VAC110-20-322. Placement of chemicals in Schedule I.*](https://law.lis.virginia.gov/admincode/title18/agency110/chapter20/section322/)
43. [â†‘](#cite_ref-43) [*Ellingtonâ€™s bill banning two deadly drugs could soon be law, State of Indiana House of Representatives*](https://www.indianahouserepublicans.com/news/press-releases/ellington-s-bill-banning-two-deadly-drugs-could-soon-be-law/)
44. [â†‘](#cite_ref-44) [*HB2033 - 531R - H Ver*](https://www.azleg.gov/legtext/53leg/1r/bills/hb2033h.htm)
45. [â†‘](#cite_ref-45) http://www.healthy.arkansas.gov/aboutADH/RulesRegs/ControlledSubstanceListSummary.pdf
46. [â†‘](#cite_ref-46) https://capitol.texas.gov/tlodocs/85R/billtext/pdf/HB02671S.pdf